San Francisco-based Cellares, which describes itself as the first Integrated Development and Manufacturing Organization, recently announced the successful completion of a $257 million Series D funding round. This capital will be used to advance the company's platform development in the cell therapy field and further solidify its market position.

This Series D funding round was co-led by investment funds managed by BlackRock and Eclipse, with participation from numerous other investors. Following this round, Cellares' total capital raised has reached $612 million, demonstrating the market's high level of recognition and anticipation for its cell therapy business. The company stated that it will use this funding to expand production capacity and enhance R&D capabilities to meet the rapidly growing global demand for cell therapies.

Cellares is committed to building a "category-defining platform" in the cell therapy field, providing the industry with efficient and reliable cell therapy solutions through integrated development and manufacturing. The success of this funding round undoubtedly injects new momentum into Cellares' development in cell therapy, enabling it to accelerate the research, development, and application of cell therapy technologies, bringing more hope to patients worldwide.